JP2018524403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524403A5 JP2018524403A5 JP2018520047A JP2018520047A JP2018524403A5 JP 2018524403 A5 JP2018524403 A5 JP 2018524403A5 JP 2018520047 A JP2018520047 A JP 2018520047A JP 2018520047 A JP2018520047 A JP 2018520047A JP 2018524403 A5 JP2018524403 A5 JP 2018524403A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- membered
- substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 125000004429 atom Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 125000001153 fluoro group Chemical group F* 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 claims description 12
- 108010011219 dUTP pyrophosphatase Proteins 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052805 deuterium Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000002018 overexpression Effects 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- -1 substituted Chemical class 0.000 description 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical group O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN740KO2015 | 2015-07-08 | ||
| IN740/KOL/2015 | 2015-07-08 | ||
| PCT/IB2016/054091 WO2017006282A1 (en) | 2015-07-08 | 2016-07-07 | Hydantoin containing deoxyuridine triphosphatase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170594A Division JP7071044B2 (ja) | 2015-07-08 | 2020-10-08 | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524403A JP2018524403A (ja) | 2018-08-30 |
| JP2018524403A5 true JP2018524403A5 (enExample) | 2019-08-22 |
| JP6836589B2 JP6836589B2 (ja) | 2021-03-03 |
Family
ID=56740270
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520047A Active JP6836589B2 (ja) | 2015-07-08 | 2016-07-07 | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
| JP2020170594A Active JP7071044B2 (ja) | 2015-07-08 | 2020-10-08 | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020170594A Active JP7071044B2 (ja) | 2015-07-08 | 2020-10-08 | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US10570098B2 (enExample) |
| EP (1) | EP3319939B1 (enExample) |
| JP (2) | JP6836589B2 (enExample) |
| CN (1) | CN107922330A (enExample) |
| AU (1) | AU2016290987C1 (enExample) |
| CA (1) | CA2991468C (enExample) |
| DK (1) | DK3319939T3 (enExample) |
| EA (1) | EA037990B1 (enExample) |
| ES (1) | ES3016670T3 (enExample) |
| FI (1) | FI3319939T3 (enExample) |
| HU (1) | HUE070225T2 (enExample) |
| IL (1) | IL256221B (enExample) |
| PL (1) | PL3319939T3 (enExample) |
| PT (1) | PT3319939T (enExample) |
| SI (1) | SI3319939T1 (enExample) |
| WO (1) | WO2017006282A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189478B (zh) | 2013-01-07 | 2019-10-22 | 南加州大学 | 脱氧尿苷三磷酸酶抑制剂 |
| US9790214B2 (en) | 2014-01-03 | 2017-10-17 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| US10570098B2 (en) | 2015-07-08 | 2020-02-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| CN109311854B (zh) | 2016-05-23 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 具有仲酰胺官能团的苯并氮杂卓二甲酰胺化合物 |
| WO2017202704A1 (en) | 2016-05-23 | 2017-11-30 | F. Hoffmann-La Roche Ag | Benzazepine dicarboxamide compounds with tertiary amide function |
| EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
| WO2018098206A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11014924B2 (en) * | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018098209A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| WO2018098208A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| CA3185648A1 (en) * | 2020-06-26 | 2021-12-30 | Cv6 Therapeutics (Ni) Limited | Combination therapy with deoxyuridine triphosphatase inhibitors |
| CN116323623B (zh) | 2020-09-18 | 2025-09-26 | 拜耳公司 | 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺 |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| US12404242B2 (en) | 2021-12-17 | 2025-09-02 | Reglagene, Inc. | Compositions and methods for making and using small molecules in the treatment of cancer |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| WO2025202022A1 (en) | 2024-03-27 | 2025-10-02 | Bayer Aktiengesellschaft | Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US100720A (en) * | 1870-03-15 | Improve ment in cultivators | ||
| JPS4829785B1 (enExample) | 1970-03-26 | 1973-09-13 | ||
| BE787766A (fr) | 1971-08-21 | 1973-02-19 | Merck Patent Gmbh | Imides d'acide glutarique et leur procede de preparation |
| US4063019A (en) * | 1976-03-30 | 1977-12-13 | E. R. Squibb & Sons, Inc. | [[[(2,4-Dioxo-1-imidazolidinyl)amino]carbonyl]amino]-acetylcephalosporin derivatives |
| US4038271A (en) | 1976-11-08 | 1977-07-26 | E. R. Squibb & Sons, Inc. | [[[(2,4-Dioxo-1-imidazolidinyl)amino]-carbonyl]amino]acetylpenicillin derivatives |
| US4304715A (en) | 1979-06-08 | 1981-12-08 | Derek Hudson | Enkephalin analogues |
| DE3027596A1 (de) | 1980-07-21 | 1982-02-18 | Bayer Ag, 5090 Leverkusen | Triazolidin-3,5-dion-oxyalkylverbindungen und verfahren zu ihrer herstellung |
| JPS5839672A (ja) | 1981-09-03 | 1983-03-08 | Chugai Pharmaceut Co Ltd | ウラシル誘導体 |
| JPS60243017A (ja) | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| JPH0674251B2 (ja) | 1986-02-07 | 1994-09-21 | 全薬工業株式▲会▼社 | ビス−ジオキソピペラジン誘導体 |
| JPS63101361A (ja) | 1986-09-08 | 1988-05-06 | ブリティッシュ・テクノロジー・グループ・リミテッド | ジオキソピペリジン誘導体を含有する不安解消組成物 |
| FR2644786B1 (fr) | 1989-03-21 | 1993-12-31 | Adir Cie | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5599796A (en) | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
| EP0793673A1 (en) | 1994-11-24 | 1997-09-10 | Takeda Chemical Industries, Ltd. | Alpha-ketoamide derivatives as cathepsin l inhibitor |
| WO1997036916A1 (en) | 1996-03-29 | 1997-10-09 | The University Of Medicine And Dentistry Of New Jersey | dUTPASE, ITS ISOFORMS, AND DIAGNOSTIC AND OTHER USES |
| JPH09286786A (ja) | 1996-04-18 | 1997-11-04 | Nippon Paper Ind Co Ltd | ピリミジン誘導体及びその抗腫瘍剤としての用途 |
| HUP0000130A2 (hu) * | 1996-08-28 | 2000-06-28 | The Procter And Gamble Co. | 1,3-Heterociklusos fémproteáz inhibitorok |
| DE19756212A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE69839221T2 (de) | 1997-12-18 | 2009-04-30 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Pyridone als hemmer der sh2-domäne der src-familie |
| EP1165500A1 (en) | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| DE10002509A1 (de) | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| HUP0400206A3 (en) | 2001-03-15 | 2004-10-28 | Astrazeneca Ab | Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them |
| JP2002284686A (ja) | 2001-03-28 | 2002-10-03 | Sankyo Co Ltd | スルホンアミド化合物を含有する医薬組成物 |
| EP1385831A2 (en) | 2001-04-11 | 2004-02-04 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| WO2004009559A2 (en) | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| US7125865B2 (en) | 2002-07-25 | 2006-10-24 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| CA2523118C (en) | 2003-04-21 | 2013-06-04 | Rgb Networks, Inc. | Wideband multi-channel quadrature amplitude modulation of cable television signals |
| GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
| DE602005027213D1 (de) * | 2004-08-03 | 2011-05-12 | Chugai Pharmaceutical Co Ltd | Neue imidazolidinderivate |
| CN101115749B (zh) * | 2004-12-17 | 2011-06-22 | 安姆根有限公司 | 氨基嘧啶化合物和使用方法 |
| KR20070099031A (ko) | 2005-01-25 | 2007-10-08 | 셀진 코포레이션 | 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물 |
| WO2006135763A2 (en) | 2005-06-09 | 2006-12-21 | The Johns Hopkins University | Inhibitors of dna repair enzymes and methods of use thereof |
| US8693525B2 (en) | 2006-07-14 | 2014-04-08 | Qualcomm Incorporated | Multi-carrier transmitter for wireless communication |
| CA2658479A1 (en) | 2006-07-24 | 2008-02-07 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
| EP1939186A1 (en) | 2006-12-22 | 2008-07-02 | Sulfidris S.r.l. | 5-Fluorouracil derivatives and their use for the treatment of cancer |
| US20090052556A1 (en) | 2007-08-23 | 2009-02-26 | Fernandez Andrew D | Frequency interleaving method for wideband signal generation |
| KR101578235B1 (ko) * | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
| PL2295414T3 (pl) | 2008-06-03 | 2013-02-28 | Taiho Pharmaceutical Co Ltd | Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól |
| WO2010025308A2 (en) | 2008-08-27 | 2010-03-04 | Universtiy Of Southern California | Inhibitors of dutpase |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| US20110306551A1 (en) | 2009-02-19 | 2011-12-15 | Novo Nordisk A/S | Modification of Factor VIII |
| FR2944524B1 (fr) * | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| US8115662B2 (en) | 2009-06-24 | 2012-02-14 | Intersil Americas Inc. | Sampler linearity by simultaneous derivative sampling |
| JP5685247B2 (ja) | 2009-06-25 | 2015-03-18 | バイオヴァーシス・アーゲーＢｉｏｖｅｒｓｙｓ Ａｇ | 結核を処置するための組成物 |
| TWI466870B (zh) | 2009-11-30 | 2015-01-01 | Taiho Pharmaceutical Co Ltd | Anti - tumor efficacy enhancer |
| JP2011111433A (ja) * | 2009-11-30 | 2011-06-09 | Taiho Yakuhin Kogyo Kk | ウレイド構造を有するウラシル化合物又はその塩 |
| JP2013032293A (ja) * | 2009-11-30 | 2013-02-14 | Taiho Yakuhin Kogyo Kk | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 |
| JP2013047189A (ja) * | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CA2834199C (en) * | 2011-07-18 | 2020-01-07 | Merck Patent Gmbh | Benzamides as allosteric modulators of the fsh receptor |
| PE20141361A1 (es) | 2011-11-15 | 2014-10-13 | Takeda Pharmaceutical | Compuesto heterociclico dihidroxi aromatico |
| US9030340B1 (en) | 2012-09-05 | 2015-05-12 | IQ-Analog Corporation | N-path interleaving analog-to-digital converter (ADC) with background calibration |
| CN105189478B (zh) * | 2013-01-07 | 2019-10-22 | 南加州大学 | 脱氧尿苷三磷酸酶抑制剂 |
| CN103435606A (zh) * | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| US9790214B2 (en) | 2014-01-03 | 2017-10-17 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| US9525940B1 (en) | 2014-03-05 | 2016-12-20 | Cirrus Logic, Inc. | Multi-path analog front end and analog-to-digital converter for a signal processing system |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| WO2016175324A1 (ja) | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| CA2984724C (en) | 2015-05-01 | 2020-06-02 | Taiho Pharmaceutical Co., Ltd. | Crystal of uracil compound |
| US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10570098B2 (en) | 2015-07-08 | 2020-02-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| KR102281961B1 (ko) | 2016-01-08 | 2021-07-26 | 다이호야쿠힌고교 가부시키가이샤 | 면역 조절제를 함유하는 항종양제 및 항종양 효과 증강제 |
| WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
-
2016
- 2016-07-07 US US15/741,202 patent/US10570098B2/en active Active
- 2016-07-07 CN CN201680051434.1A patent/CN107922330A/zh active Pending
- 2016-07-07 HU HUE16753974A patent/HUE070225T2/hu unknown
- 2016-07-07 EA EA201890247A patent/EA037990B1/ru not_active IP Right Cessation
- 2016-07-07 EP EP16753974.1A patent/EP3319939B1/en active Active
- 2016-07-07 PL PL16753974.1T patent/PL3319939T3/pl unknown
- 2016-07-07 SI SI201631891T patent/SI3319939T1/sl unknown
- 2016-07-07 CA CA2991468A patent/CA2991468C/en active Active
- 2016-07-07 JP JP2018520047A patent/JP6836589B2/ja active Active
- 2016-07-07 PT PT167539741T patent/PT3319939T/pt unknown
- 2016-07-07 ES ES16753974T patent/ES3016670T3/es active Active
- 2016-07-07 AU AU2016290987A patent/AU2016290987C1/en active Active
- 2016-07-07 DK DK16753974.1T patent/DK3319939T3/da active
- 2016-07-07 FI FIEP16753974.1T patent/FI3319939T3/fi active
- 2016-07-07 WO PCT/IB2016/054091 patent/WO2017006282A1/en not_active Ceased
-
2017
- 2017-12-10 IL IL256221A patent/IL256221B/en active IP Right Grant
-
2018
- 2018-03-07 US US15/914,958 patent/US10562860B2/en not_active Expired - Fee Related
-
2020
- 2020-05-04 US US16/789,687 patent/US11104649B2/en active Active
- 2020-10-08 JP JP2020170594A patent/JP7071044B2/ja active Active
-
2021
- 2021-05-14 US US17/320,650 patent/US11584723B2/en active Active
-
2022
- 2022-12-05 US US18/075,316 patent/US12098133B2/en active Active
-
2024
- 2024-08-16 US US18/807,770 patent/US20250188039A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524403A5 (enExample) | ||
| JP6806562B2 (ja) | ｅＩＦ２α経路の調節因子 | |
| RU2768827C2 (ru) | Модуляторы хемокинового рецептора и их применение | |
| RU2581834C1 (ru) | Новое пиперидиновое соединение или его соль | |
| US20220193242A1 (en) | Immunophilin-dependent inhibitors and uses thereof | |
| JP2022141811A5 (enExample) | ||
| IL277783B2 (en) | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations | |
| PT1940789E (pt) | Métodos e compostos para preparar análogos cc-1065 | |
| JP2008535902A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| EP4473980A3 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| CN107001331A (zh) | 作为bub1抑制剂的苄基取代的吲唑 | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| EP3411046B1 (en) | Rapaglutins, novel inhibitors of glut and use thereof | |
| KR20210029165A (ko) | 비아릴에테르형 퀴나졸린 유도체 | |
| JP2017535514A (ja) | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 | |
| JP2017502967A5 (enExample) | ||
| JP2017516859A (ja) | １，３，４−チアジアゾール化合物および癌を治療する際のその使用 | |
| JPWO2020028608A5 (enExample) | ||
| RU2017109355A (ru) | Гетероциклические соединения и их применение | |
| ES2759940T3 (es) | Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer | |
| JP2017137323A (ja) | 新規抗がん剤 | |
| EP4032890A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| US11739121B2 (en) | EPHA2 agonists and uses thereof | |
| AU2019216757A1 (en) | Mebendazole prodrugs with enhanced solubility and oral bioavailability |